Education
About Us
Working with TipRanks
Follow Us
Surgical Science Sweden AB (SE:SUS)
:SUS
Earnings Data
Report Date
May 20, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.37Last Year’s EPS
0.68Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of clear operational and commercial progress (record license revenue, FX-adjusted sales growth, strong Americas rebound, price increases, larger development pipeline, healthy cash position and Q4 profitability in line with targets) alongside material near-term headwinds (the Intuitive dV5 MOU cancellation with an estimated SEK 60–90m 2026 revenue impact, full-year margin decline vs prior year, IU integration losses and significant declines in certain simulator sales, and notable FX pressure). The company emphasized strategy execution, pipeline strength and cost actions, but the Intuitive-related revenue uncertainty and full-year profitability erosion are sizable concerns for 2026.Company Guidance
Quarterly Sales Growth (FX-adjusted)
Q4 sales of SEK 269 million, up 15% in local currencies (7% reported). Full-year sales SEK 992 million, up 12% reported (19% in local currencies).
Record License Revenues (Robotics)
All-time high license revenues of SEK 92 million in Q4, an increase of 21%; license revenues represented 34% of total revenues in the quarter (30% prior year).
Adjusted EBIT and Profitability in Q4
Adjusted EBIT for Q4 of SEK 46 million. Reported adjusted EBIT margin cited at ~17% (18% excluding restructuring), with operating profit of SEK 40 million (15% margin) — Q4 results aligned with the company target of >15% profitability.
Pricing and Margin Initiatives
Average sales prices increased by ~9% vs Q4 2024 at fixed exchange rates with no significant volume impact; company expects further positive price effects going forward.
Regional Outperformance — Americas
North and South America region grew 43% in Q4 driven by the U.S., indicating a clear recovery and stronger sales pipelines in the region.
Strong Robotics Pipeline and Product Rollouts
Surgical Science has relationships with ~20 robotics companies (about 5 bought licenses in Q4), launched RobotiX Express with 14 exercises, and highlighted growing adoption of robotics (Intuitive reported 18% procedure growth; broader market expansion with multiple new robot models).
Development Revenue Momentum and Customer Retention
Development revenues were strong in Q4; pipeline of ongoing development projects was ~15% larger vs year-end 2024 and repeat customers for development projects exceeded 70%, indicating strong customer retention.
Cash Position and Operating Cash Flow
Operating cash flow of SEK 73 million in Q4 (vs SEK 57 million prior year Q4). Year-end cash balance SEK 616 million, providing liquidity to execute strategy.
SE:SUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:SUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | kr24.88 | kr29.10 | +16.96% |
Nov 13, 2025 | kr84.15 | kr74.20 | -11.82% |
Aug 21, 2025 | kr100.00 | kr100.60 | +0.60% |
May 14, 2025 | kr143.00 | kr150.70 | +5.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Surgical Science Sweden AB (SE:SUS) report earnings?
Surgical Science Sweden AB (SE:SUS) is schdueled to report earning on May 20, 2026, TBA (Confirmed).
What is Surgical Science Sweden AB (SE:SUS) earnings time?
Surgical Science Sweden AB (SE:SUS) earnings time is at May 20, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Surgical Science Sweden AB stock?
The P/E ratio of Surgical Science Sweden AB is N/A.
What is SE:SUS EPS forecast?
SE:SUS EPS forecast for the fiscal quarter 2026 (Q1) is 0.37.